fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-07-09 I-II Result Biogen Idec (USA) Swedish Orphan Biovitrum (Sweden)   recombinant factor VIII Fc fusion protein (rFVIIIFc) hemophilia A   See details
2010-07-07 III Launch Karo Bio (Sweden)   eprotirome (selective thyroid hormone antagonist - KB2115) heterozygous familial hypercholesterolemia Europe See details
2010-07-07 I Launch NOXXON Pharma (Germany)   NOX-E36 (Spiegelmer® MCP-1 antagonist that specifically targets the pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1), which is also known as CCL2). diabetic nephropathy and other diabetes related complications Germany See details
2010-07-06 II Result Genmab (Denmark)   ofatumumab relapsing-remitting multiple sclerosis   See details
2010-07-02 II Result Intercell (Austria)   Vaccine enhancement patch in combination with an injectable H5N1 pandemic influenza vaccine Pandemic influenza USA See details
2010-06-22 I-II Launch Mologen (Germany)   MGN1601 (cell-based gene therapy) The product has been granted orphan drug status by EMA. Renal cancer Germany See details
2010-06-22 III Launch Novo Nordisk (Denmark)   Victoza® (liraglutide - human glucagon-like-peptide 1 analogue) obesity   See details
2010-06-22 II Launch Mologen (Germany)   MGN1703 (cancer immunotherapy based on dSLIM® immunomodulator, which is an agonist of the Toll-like receptor 9 involved in innate immunity) Colorectal cancer Austria, Germany, Great Britain, Russia and other countries See details
2010-06-18 II Result   Novartis (Switzerland) ACZ885 - human monoclonal antibody ACZ885 (canakinumab) gout   See details
2010-06-17 I Result Mymetics Corporation (Switzerland)   virosome-based vaccine. Mymetics’ Malaria vaccine uses influenza-based virosomes as the antigen carrier—already approved as a vaccine carrier in more than 40 countries—with two synthetic peptide vaccine components that mimic the native structure of important antigens found during the key stages in the Malaria parasite’s life cycle. malaria Tanzania See details
2010-06-16 Other Result Santhera Pharmaceuticals (Switzerland)   Catena® Leber's Hereditary Optic Neuropathy(LHON) UK, Germany, Canada See details
2010-06-16 IIb Result Immunomedics (USA) UCB (Belgium) epratuzumab (humanised monoclonal antibody targeting CD22) systemic lupus erythematosus   See details
2010-06-15 I Launch Pieris (Germany)   PRS-050 (anti-VEGF (Vascular Endothelial Growth Factor) Anticalin®) solid tumors Germany See details
2010-06-11 I Launch Topotarget (Denmark)   belinostat in combination with bortezomib (Velcade®) Acute Leukemia or Myelodysplastic Syndromes USA See details
2010-06-08 I-II Result Mologen (Germany)   MGN1703 (cancer immunotherapy based on dSLIM® immunomodulator, which is an agonist of the Toll-like receptor 9 involved in innate immunity) advanced metastatic tumors Germany See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]